Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells
- PMID: 22629385
- PMCID: PMC3357420
- DOI: 10.1371/journal.pone.0037361
Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells
Abstract
Development of bone metastases is dependent on the cancer cell-bone cell interactions in the bone microenvironment. Transforming growth factor β (TGF-β) is released from bone during osteoclastic bone resorption and induces production of osteolytic factors, such as interleukin 11 (IL-11), in breast cancer cells. IL-11 in turn increases osteolysis by stimulating osteoclast function, launching a vicious cycle of cancer growth and bone destruction. We aimed to identify and functionally characterize microRNAs (miRNAs) that mediate the bone metastatic process, focusing on miRNAs that regulate the TGF-β induction of IL-11. First, we profiled the expression of 455 miRNAs in a highly bone metastatic MDA-MB-231(SA) variant as compared to the parental MDA-MB-231 breast cancer cell line and found 16 miRNAs (3.5%) having a >3-fold expression difference between the two cell types. We then applied a cell-based overexpression screen with Pre-miRNA constructs to functionally identify miRNAs regulating TGF-β-induced IL-11 production. This analysis pinpointed miR-204, miR-211, and miR-379 as such key regulators. These miRNAs were shown to directly target IL11 by binding to its 3' UTR. MiR-379 also inhibited Smad2/3/4-mediated transcriptional activity. Gene expression analysis of miR-204 and miR-379-transfected cells indicated that these miRNAs downregulated the expression of several genes involved in TGF-β signaling, including prostaglandin-endoperoxide synthase 2 (PTGS2). In addition, there was a significant correlation between the genes downregulated by miR-379 and a set of genes upregulated in basal subtype of breast cancer. Taken together, the functional evidence and clinical correlations imply novel mechanistic links between miRNAs and the key steps in the bone metastatic process in breast cancer, with potential clinical relevance.
Conflict of interest statement
Figures





Similar articles
-
Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.Mol Cancer Res. 2012 May;10(5):597-604. doi: 10.1158/1541-7786.MCR-11-0482. Epub 2012 Apr 20. Mol Cancer Res. 2012. PMID: 22522458
-
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.Oncogene. 2012 Sep 13;31(37):4150-63. doi: 10.1038/onc.2011.571. Epub 2011 Dec 12. Oncogene. 2012. PMID: 22158050
-
Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.Cancer Res. 2015 Apr 1;75(7):1433-44. doi: 10.1158/0008-5472.CAN-14-1026. Epub 2015 Jan 29. Cancer Res. 2015. PMID: 25634212 Free PMC article.
-
Parathyroid hormone-related protein and bone metastases.Cancer. 1997 Oct 15;80(8 Suppl):1572-80. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1572::aid-cncr7>3.3.co;2-d. Cancer. 1997. PMID: 9362424 Review.
-
Transforming growth factor-beta in osteolytic breast cancer bone metastases.Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S32-8. doi: 10.1097/01.blo.0000093055.96273.69. Clin Orthop Relat Res. 2003. PMID: 14600590 Review.
Cited by
-
What Is the Role of Interleukins in Breast Cancer Bone Metastases? A Systematic Review of Preclinical and Clinical Evidence.Cancers (Basel). 2019 Dec 13;11(12):2018. doi: 10.3390/cancers11122018. Cancers (Basel). 2019. PMID: 31847214 Free PMC article. Review.
-
Emerging Evidence of the Functional Impact of the miR379/miR656 Cluster (C14MC) in Breast Cancer.Biomedicines. 2021 Jul 16;9(7):827. doi: 10.3390/biomedicines9070827. Biomedicines. 2021. PMID: 34356891 Free PMC article. Review.
-
miR-379 regulates cyclin B1 expression and is decreased in breast cancer.PLoS One. 2013 Jul 10;8(7):e68753. doi: 10.1371/journal.pone.0068753. Print 2013. PLoS One. 2013. PMID: 23874748 Free PMC article.
-
Somatic Mutations in miRNA Genes in Lung Cancer-Potential Functional Consequences of Non-Coding Sequence Variants.Cancers (Basel). 2019 Jun 8;11(6):793. doi: 10.3390/cancers11060793. Cancers (Basel). 2019. PMID: 31181801 Free PMC article.
-
MicroRNA and Breast Cancer: Understanding Pathogenesis, Improving Management.Noncoding RNA. 2015 Apr 20;1(1):17-43. doi: 10.3390/ncrna1010017. Noncoding RNA. 2015. PMID: 29861413 Free PMC article. Review.
References
-
- Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet. 2007;8:601–609. DOI: 10.1038/nrg2137. - DOI - PubMed
-
- Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601. DOI: 10.1038/ncb1722. - DOI - PubMed
-
- Wang L, Wang J. MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene. DOI: 10.1038/ 2011;onc.2011.444 10.1038/onc.2011.444. - PubMed
-
- Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–152. DOI: 10.1038/nature06487. - DOI - PMC - PubMed
-
- Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 2009;28:347–358. DOI: 10.1038/emboj.2008.294. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous